Stocksigma LogoStocksigma Logo

3B BlackBio Dx Reports Strong Q2 FY27 Results Driven by Diagnostic Growth

For Q2 ended 30th Sep'26, 3B BlackBio Dx posted consolidated revenue from operations of ₹4,828.02 lakh, surging 42.4% YoY and 44.2% QoQ

3B BlackBio Dx Reports Strong Q2 FY27 Results Driven by Diagnostic Growth

3B BlackBio Dx Ltd · Financial Result · 13 Nov 2026, 10:27 pm

3B BlackBio Dx Reports Strong Q2 FY27 Results Driven by Diagnostic Growth For Q2 ended 30th Sep'26, 3B BlackBio Dx posted consolidated revenue from operations of ₹4,828.02 lakh, surging 42.4% YoY and 44.2% QoQ. Net profit rose 19.9% YoY and 100.7% QoQ to ₹1,802.33 lakh, with EPS at ₹21.03. Growth was led by Diagnostic Kits, delivering revenue of ₹4,502.48 lakh (up 48.0% YoY) and segment EBIT of ₹2,442.46 lakh, while Agrochemicals posted a slight EBIT loss of ₹6.82 lakh. For H1 ended 30th Sep'26, consolidated revenue reached ₹8,177.10 lakh with a net profit of ₹2,700.17 lakh.

Original exchange filing (PDF)

More announcements from 3B BlackBio Dx Ltd

All 3B BlackBio Dx Ltd announcements